Sunscreen: the one with real trial evidence

Most skincare ingredients are sold on cell-culture studies and short instrument readings. Sunscreen is the exception: it has randomized controlled trials in real people, with hard endpoints, run over years.

24% less photoaging — a randomized trial

In Nambour, Australia, 903 adults under 55 were randomly assigned to daily broad-spectrum sunscreen or discretionary (use-it-when-you-like) application, and followed for 4.5 years. Skin aging was measured by surface micro-topography. The daily-use group showed 24% less photoaging than the discretionary group. Not a survey, not a lab model — a controlled trial measuring real skin.

Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Annals of Internal Medicine, 2013. PubMed 23732711

Half the melanoma — ten years on

The same trial population was followed for a decade. Regular sunscreen use roughly halved melanoma incidence, with the strongest protection against invasive melanoma. It remains the landmark randomized evidence that sunscreen prevents the deadliest skin cancer, not just sunburn.

Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. Journal of Clinical Oncology, 2011. PubMed 21135266

What this means on the awarded shelf

This is why sun care is the one category where we state an effect size. The award winners we track — the awarded products filed under SPF — differ in texture, finish and price, but the underlying intervention is the best-evidenced habit in all of skincare: daily application.